BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9563724)

  • 21. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
    Wang Y; Zhang XR; Fu J; Tan W; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.
    Tomizawa Y; Kohno T; Fujita T; Kiyama M; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Nakajima T; Yokota J
    Oncogene; 1999 Jan; 18(4):1007-14. PubMed ID: 10023676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skip metastasis in nonsmall cell lung carcinoma: predictive markers and isolated tumor cells in N1 lymph nodes.
    Prenzel KL; Baldus SE; Mönig SP; Tack D; Sinning JM; Gutschow CA; Grass G; Schneider PM; Dienes HP; Hölscher AH
    Cancer; 2004 May; 100(9):1909-17. PubMed ID: 15112272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer.
    Borner MM; Brousset P; Pfanner-Meyer B; Bacchi M; Vonlanthen S; Hotz MA; Altermatt HJ; Schlaifer D; Reed JC; Betticher DC
    Br J Cancer; 1999 Feb; 79(5-6):952-8. PubMed ID: 10070896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma.
    Wang X; Christiani DC; Mark EJ; Nelson H; Wiencke JK; Gunn L; Wain JC; Kelsey KT
    Cancer; 1999 Apr; 85(8):1734-9. PubMed ID: 10223567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma.
    Törmänen U; Eerola AK; Rainio P; Vähäkangas K; Soini Y; Sormunen R; Bloigu R; Lehto VP; Pääkkö P
    Cancer Res; 1995 Dec; 55(23):5595-602. PubMed ID: 7585640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers.
    Kitagawa Y; Wong F; Lo P; Elliott M; Verburgt LM; Hogg JC; Daya M
    Am J Respir Cell Mol Biol; 1996 Jul; 15(1):45-54. PubMed ID: 8679221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
    Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas.
    Bongiorno PF; Whyte RI; Lesser EJ; Moore JH; Orringer MB; Beer DG
    J Thorac Cardiovasc Surg; 1994 Feb; 107(2):590-5. PubMed ID: 7905543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
    Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
    Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
    Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y
    Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer.
    Mitsudomi T; Oyama T; Kusano T; Osaki T; Nakanishi R; Shirakusa T
    J Natl Cancer Inst; 1993 Dec; 85(24):2018-23. PubMed ID: 8246288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
    Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
    Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neural networks as a prognostic tool for patients with non-small cell carcinoma of the lung.
    Bellotti M; Elsner B; Paez De Lima A; Esteva H; Marchevsky AM
    Mod Pathol; 1997 Dec; 10(12):1221-7. PubMed ID: 9436967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunocytochemical markers in stage I lung cancer: relevance to prognosis.
    Pastorino U; Andreola S; Tagliabue E; Pezzella F; Incarbone M; Sozzi G; Buyse M; Menard S; Pierotti M; Rilke F
    J Clin Oncol; 1997 Aug; 15(8):2858-65. PubMed ID: 9256129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer.
    Laudanski J; Niklinska W; Burzykowski T; Chyczewski L; Niklinski J
    Eur Respir J; 2001 Apr; 17(4):660-6. PubMed ID: 11401061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.